Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI
12:00pm, Tuesday, 14'th Oct 2025
SUMMIT, N.J. & OAKLAND, Calif.--(BUSINESS WIRE)--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec�
Trump's Tylenol claims limit M&A options for parent company Kenvue
06:05am, Tuesday, 14'th Oct 2025
Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.
Is This Beaten-Down Dividend King a Buy?
04:19am, Friday, 10'th Oct 2025
In today's uncertain economic environment, investing in robust dividend stocks can be a great hedge. Companies that can consistently issue growing payouts tend to have strong underlying businesses cap
Buy 2 Ideal Dividend Kings Of 25 'Safer' In October's 56
12:51am, Friday, 10'th Oct 2025
This October's Dividend Kings list features 56 stocks, with Kenvue and United Bankshares meeting the ideal "fair price" yield criteria. Analysts project the top-ten Dividend Kings could deliver 19.2%
US Republicans and Democrats split on party lines on Trump's Tylenol-autism claim, KFF poll finds
10:58am, Thursday, 09'th Oct 2025
Republicans and Democrats are divided along party lines as to whether they believe the U.S. government's claim that women who take Tylenol during pregnancy are raising the risk of autism in their unbo
These Were the 5 Worst-Performing Stocks in the S&P 500 in September 2025 -- and One's Decline Can Be Tied to President Trump
09:13am, Wednesday, 08'th Oct 2025
It's fun to follow stocks that soared recently, and it can be sobering to see which ones have plunged -- especially if you're a shareholder. So here's a look at the worst-performing stocks in the S&P
Near 52-Week Low, Should You Buy Kenvue Stock?
05:45am, Wednesday, 08'th Oct 2025
Investors are wondering if the recent weakness in Kenvue (KVUE 3.28%) stock is a buying opportunity for long-term buyers.
Why Is Kenvue Stock Falling, and Is It a Buying Opportunity?
09:50am, Tuesday, 07'th Oct 2025
Kenvue (KVUE 2.61%) is under attack by the government, which accuses the company of selling unsafe products to pregnant women.
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
09:31am, Friday, 03'rd Oct 2025
In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.
Should You Buy Kenvue Stock After Its 30% Plunge?
04:44am, Wednesday, 01'st Oct 2025
Johnson & Johnson (JNJ 2.09%) spun off its consumer health unit as a separate entity in 2023. The new business, Kenvue (KVUE -0.77%), inherited a broad lineup of popular products, including Band-Aid a
Cullen Trims KVUE Stake With $149.5M Share Sale
12:29am, Wednesday, 01'st Oct 2025
Cullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.
Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain
08:00am, Saturday, 27'th Sep 2025
Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core
These U.S. politicians dumped Tylenol maker shares before Trump's autism warning
07:43am, Saturday, 27'th Sep 2025
A pair of United States lawmakers sold shares in Tylenol's parent company, Kenvue (NYSE: KVUE), just days before President Donald Trump made controversial remarks linking the painkiller to autism.
What Moved Markets This Week
07:02am, Saturday, 27'th Sep 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
09:00pm, Friday, 26'th Sep 2025
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
